Geron Corp. Files 8-K on Executive Changes, Compensation

TL;DR

**Geron Corp. just filed an 8-K about executive changes and compensation, signaling potential shifts.**

AI Summary

Geron Corp. filed an 8-K on March 26, 2026, to report an event under Item 5.02, which typically covers changes in directors or officers and their compensation. While the specific details of the departure, election, or appointment, and any compensatory arrangements are not explicitly detailed in this summary, the filing indicates a significant corporate governance or executive compensation event occurred on March 25, 2026. This matters to investors because changes in leadership or executive pay can signal shifts in company strategy, financial health, or future performance, potentially impacting stock valuation.

Why It Matters

Changes in executive leadership or compensation can directly influence a company's strategic direction and operational stability, which are key factors for stock performance.

Risk Assessment

Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty regarding future company direction and stability.

Analyst Insight

Investors should seek out the full text of the 8-K filing to understand the specific details of the executive changes or compensation arrangements, as these details will determine the actual impact on the company.

Key Players & Entities

• GERON CORP (company) — the filer of the 8-K
• 0000886744 (company) — CIK of Geron Corp.
• 0001193125-26-125151 (dollar_amount) — SEC Accession No. for the filing

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Mar

Filing Documents

• d192220d8k.htm (8-K) — 27KB
• 0001193125-26-125151.txt ( ) — 140KB
• gern-20260325.xsd (EX-101.SCH) — 3KB
• gern-20260325_lab.xml (EX-101.LAB) — 18KB
• gern-20260325_pre.xml (EX-101.PRE) — 11KB
• d192220d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 25, 2026 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 919 E. HILLSDALE BLVD. , SUITE 250 FOSTER CITY , CALIFORNIA 94404 (Address of principal executive offices, including zip code) (650) 473-7700 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Directors On March 25, 2026, the Board of Directors (the "Board") of Geron Corporation (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Patricia S. Andrews and Constantine Chinoporos to the Board, in each case effective immediately, and each as a Class III director for a term expiring at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). In connection with her election to the Board, Ms. Andrews was appointed as a member of the Audit Committee of the Board with immediate effect. There are no arrangements or understandings between either Ms. Andrews or Mr. Chinoporos and any other person pursuant to which either Ms. Andrews or Mr. Chinoporos was elected as a director of the Company. Each of Ms. Andrews and Mr. Chinoporos will receive cash and equity compensation for their respective service on the Board and its committees in accordance with the Company's standard compensatory arrangements for non-employee directors as described under the section titled "Compensation of Directors" in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 8, 2025. In connection with their respective elections, the Company and each of Ms. Andrews and Mr. Chinoporos will enter into the Company's standard form of indemnification agreement. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify each of Ms. Andrews and Mr. Chinoporos for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by them in any action or proceeding arising out of their service as directors of the Company. The foregoing is only a brief description of the terms of the Company's standard form of indemnification agreement, does not purport to be complete, and is qualified in its entirety by reference to the form of indemnification agreement, previously filed as Exhibit 10.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on March 7, 2012. Biographical information for each of Ms. Andrews and Mr. Chinoporos is as follows: Ms. Andrews currently serves as a member of the Board of Directors of Glenmark Pharmaceuticals Limited, and as a director of its wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), positions she has held since August 2025. Since 2024, she has also served as a member of the Board of Directors of Oncolytics Biotech Inc. Previously, she served as a member of the Board of Directors and the Audit Committee of GlycoMimetics, Inc., from 2017 until its merger with Crescent Biopharma in 2025. Ms. Andrews served as Chief Executive Offic

View Full Filing

View this 8-K filing on SEC EDGAR